Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rebouche, C. J.
Right arrow Articles by Engel, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rebouche, C. J.
Right arrow Articles by Engel, A. G.
NEUROLOGY 1981;31:813
© 1981 American Academy of Neurology

Primary systemic carnitine deficiency

I. Carnitine biosynthesis

Charles J. Rebouche, Ph.D. and Andrew G. Engel, M.D.

Neuromuscular Research Laboratory and Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, MN 55901.

[methyl-3H]{varepsilon}-N-trimethyl-1-lysine was administered to patients with primary systemic carnitine deficiency and to controls. In both groups, labeled carnitine appeared in blood and urine within 2 hours, and the specific radioactivity of urinary carnitine peaked between 2 and 6 hours. The specific radioactivity of serum carnitine peaked at 6 hours in the controls and in one patient, but in the other patient it rose sharply in the first 2 hours, fell slightly, and then gradually increased to a maximum at 48 hours. The 48-hour excretion of [methyl-3H]-1-carnitine was 4.4 to 6.0 µCi for the controls and 24.2 and 5.6 µCi for patients A and B, respectively. Eight other radioactive metabolites were found in urines of all subjects. Each metabolite was present in comparable amounts. Primary systemic carnitine deficiency in these patients did not result from defective biosynthesis or abnormal degradation of carnitine.

Address correspondence and reprint requests to Dr. Rebouche, Mayo Clinic, Rochester, MN 55901.

This work was supported by a Research Center Grant from the Muscular Dystrophy Association and National Institutes of Health Grants Nos. NS 06277 and AM 27451.

Accepted for publication October 21, 1980.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1981 by AAN Enterprises, Inc.